- PROFESSOR | Medicine, Cardiology
- Indian (Hindi)
- Hospital Affiliation
- The Mount Sinai Hospital
- Cardiovascular Medicine Associates 212-427-1540212-427-1540
Dr. Annapoorna S. Kini performs over 1,000 minimally invasive coronary interventions annually (the highest number by a female interventionalist in the United States) with extremely low complication rate, less than 0.5 percent. She is well known for performing the complex coronary interventions in advanced heart disease patients including chronic total occlusion (CTO) procedures with utmost safety and excellent long-term results. Dr. Kini also specializes in the non-coronary interventions of mitral and aortic balloon valvuloplasty, and alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
As Director of the The Cardiac Catheterization Laboratory at The Mount Sinai Hospital she is responsible for day-to-day smooth functioning of a very high volume Cardiac Cath Lab which performs more than 15,000 total procedures including 5,200 interventions. Dr. Kini also serves as the Director of Interventional Cardiology Fellowship Program involving seven-to-nine fellows from the United States and overseas. Mount Sinai fellowship is one of the largest and Dr. Kini is responsible for selection and training of these fellows.
Dr. Kini played a key role in starting the Live Symposium of Complex Coronary Cases in 1998, which has had overwhelming success every year by performing live complex coronary cases. She is the director of the live monthly and bi-monthly webcast series titled, Complex Coronary Cases and Structural Heart Live Cases. These live cases are broadcast to over 131 countries and receive over 7,000 page views.
Dr. Kini is widely published on various topics of Interventional Cardiology, including peri-procedural enzyme elevations, rotational atheretomy, other newer devices, contrast nephropathy, and valvuloplasties. She has authored numerous book chapters in the field of acute coronary syndrome and coronary interventions. She serves as the site Principal Investigator for numerous multicenter trials including NIH sponsored trials. She maintains a large interventional database of more than 30,000 PCI patients, which helps in analysis and publications of short and long term outcomes after all kinds of coronary interventions.
Dr. Kini is recipient of the Young Investigator Award of American Association of Cardiology of Indian Origin (AAICO) in 1999. In 2014, Dr. Kini received the prestigious Physician of the Year Award from the Mount Sinai Heart Nursing Department.
Dr. Kini received her medical degree from Kasurba Medical College, Mangalore, India. She was the best outgoing student having received three honors and gold medals. She then strengthened her clinical cardiology training in England and became the member of the Royal College of Physicians of London.
- Acute Coronary Syndrome
- Atherectomy coronary vessel
- Cardiac Catherization
- Chronic Total Occlusion
- Coronary Angioplasty
- Heart Attack/Acute Coronary Syndrome
- Hyperthropic Cardiomyopathy
- Mitral Stenosis
- Mitral Valve Disease
- Transcatheter Aortic Valve Replacement (TAVR)
- Valvular Heart Disease
MBBS, Kasturba Medical College
Internship, Internal Medicine
Kasturba Medical College
University of Wales College of Med
Residency, Internal Medicine
Our Lady of Mercy Med. Center merged Montefiore North
Mount Sinai Hospital
Fellowship, Cardiovascular Dis.
Mount Sinai Hospital
Fellowship, Interventional Radiology
Mount Sinai Hospital
English, Indian (Hindi), Spanish
A non-randomized, single-blinded, open-label, investigator-initiated, pre-marketing, single-center, crossed-over Phase III clinical trial of the 12-Lead ECG Glove (12-LEG) for the assessment of cardiac electrical function. (EKG Glove Study)
The purpose of this study is to compare the computer interpretation results of two different types of ECG's. An ECG is an electrical map of your heart showing the movement of the heart muscle at each heartbeat. The study will determine if the 12LEG is the same as or better than t...
Chronometric Observations of Lipid Core Containing Plaques of Interest in Native Coronary Arteries Registry (COLOR Registry)
The purpose of this study is to improve the medical knowledge of the behavior and role of lipid cores and deposits (fatty materials) in the coronary arteries on the heart health of patients. This will be done by setting up a registry (a database) called the COLOR Registry. The pu...
Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy (YELLOW Trial)
The purpose of this study is to compare the effects of statin therapy with Rosuvastatin (Crestor) versus the standard statin therapies of Atorvastatin (Lipitor) and Simvastatin (Zocor) on lowering your cholesterol levels. Each of these statin therapies is Food and Drug Administra...
JOSTENT Coronary Stent Graft
The JOSTENT is a coronary stent graft for commercial use in select patients through a Humanitarian Device Exemption (HDE). The device has been approved for use in the treatment of free perforation, defined as free contrast extravasations into the pericardium, in native vessels or...
Coronary Assessment by Near infrared of Atherosclerotic Rupture-prone Yellow [CANARY Trial]
The purpose of the study is to test the use of an investigational device, called an embolic protection device (EPD-Filterwire EZ), that removes the debris in the blood vessel during a procedure called Percutaneous Coronary Intervention (PCI). During PCI, a metal mesh ...
A Prospective Randomized Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS element) for the Treatment of up to Two De Novo Coronary Artery Lesions - PLATINUM Trial
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. ClinicalTrials.gov Identifier: NCT00823212
Kini A, Kim M, Sharma S, Krishnan P, Ivan O, Moreno P. Comparison of Coronary Flow Reserve and Fractional Flow Reserve in Patients With Versus Without Diabetes Mellitus and Having Elective Percutaneous Coronary Intervention and Abciximab Therapy (From the PREDICT Trial). Am J Cardiol 2008;.
Kini A, Moreno P, Steinheimer A, Sharma S, Suleman J, Kim M, Prattipati M. Effectiveness of the Stent Pull-Back Technique for Non-Aorto Ostial Coronary Narrowings. Am J Cardiol 2005; 96: 1123-1128.
Lee P, Kini A, Sharma S, Fisher E, Ahsan C. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Col Cardiol 2004; 44: 541.
Kini A, Lee P, Marmur J, Sharma S, Duffy M, Kim M, Agarwal A. Correlation of postpercutaneous coronary intervention creatine Kinase-MB and Troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93: 18.
Kini A, Lee P, Sharma S, Duffy M, Mitre C. Post-procedure chest pain following coronary stenting: Implications on clinical restenosis. J Am Coll Cardiol 2003; 41: 33.
Kini A, Richard M, Suleman J, Sharma SK, Lee P, Kamran M, Marmur JD, Perez N. Effectiveness of tirofiban, eptifibatide, abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol 2003; 41: 33.
Kini A, Sharma S, Mitre C, Reich D. A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria. Am J Cardiol 2001; 88: 1287.
Kini A, Sharma S, Marmur J, Reich D. Does abciximab limit the CK-MB elevation after rotational atherectomy of type B2 lesions? Results of the Rota ReoPro randomized trial. Am Heart J 2001; 142: 965.
Kini A, Marmur J, Kini S, Dangas G, Sharma S, Cocke T, Brown E, Ambrose J, Wallenstein S. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis and low-to-medium level elevation has a benign clinical course: Implication for early discharge after coronary intervention. J Am Coll Cardiol 1999; 34: 663.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Kini did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.